Emalex Biosciences   Report issue

For profit Phase 1 Phase 3
Founded: Northbrook IL United States (2010)

Organization Overview

First Clinical Trial
2019
NCT04007991
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Emalex Biosciences Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

Key: Emalex Biosciences (0) Acquired (1)

ecopipam (16 trials)

Drugs in Phase 1 Trials (4)

Key: Emalex Biosciences (3) Acquired (1)

mefenamic acid (ponstel) (1 trial)

moxifloxacin (avelox) (1 trial)

rifampin (1 trial)

valproic acid (depakene) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Childhood-Onset Fluency Disorder (Phase 2)

Stuttering (Phase 2)

Syndrome (Phase 2)

Tourette Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 17
  • # of Trial APIs: 5